Business Description
Johnson & Johnson
NAICS : 325412
SIC : 2834
Compare
Compare
Traded in other countries / regions
JNJ.USAJNJ.ArgentinaJNJ.Canada0R34.UKJNJB34.BrazilJNJ.GermanyJNJ.Mexico1JNJ.ItalyJNJ.PeruJNJ.AustriaJNJ.ChileJNJ_KZ.KazakhstanJNJ.BulgariaJNJ.SwitzerlandJNJCO.ColombiaJNJ.Ukraine IPO Date
2021-11-12Description
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.42 |
N/A
|
N/A
| |||
Equity-to-Asset | 0.42 |
N/A
|
N/A
| |||
Debt-to-Equity | 0.58 |
N/A
|
N/A
| |||
Debt-to-EBITDA | 1.44 |
N/A
|
N/A
| |||
Interest Coverage | 25.94 |
N/A
|
N/A
| |||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 4.18 | |||||
Beneish M-Score | -2.55 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 8.9 | |||||
3-Year EBITDA Growth Rate | 19.2 |
N/A
|
N/A
| |||
3-Year EPS without NRI Growth Rate | 2.1 |
N/A
|
N/A
| |||
3-Year FCF Growth Rate | 7.2 |
N/A
|
N/A
| |||
3-Year Book Growth Rate | 4.8 |
N/A
|
N/A
| |||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 8.63 |
N/A
|
N/A
|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 57.81 |
N/A
|
N/A
| |||
9-Day RSI | 56.82 |
N/A
|
N/A
| |||
14-Day RSI | 56.71 |
N/A
|
N/A
| |||
3-1 Month Momentum % | 16.22 |
N/A
|
N/A
| |||
6-1 Month Momentum % | 10.33 |
N/A
|
N/A
| |||
12-1 Month Momentum % | 53.73 |
N/A
|
N/A
|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.09 |
N/A
|
N/A
| |||
Quick Ratio | 0.81 |
N/A
|
N/A
| |||
Cash Ratio | 0.38 |
N/A
|
N/A
| |||
Days Inventory | 166.02 |
N/A
|
N/A
| |||
Days Sales Outstanding | 66.64 |
N/A
|
N/A
| |||
Days Payable | 117.91 |
N/A
|
N/A
|
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 1.94 |
N/A
|
N/A
| |||
Dividend Payout Ratio | 0.5 |
N/A
|
N/A
| |||
3-Year Dividend Growth Rate | 4.9 |
N/A
|
N/A
| |||
Forward Dividend Yield % | 1.99 |
N/A
|
N/A
| |||
5-Year Yield-on-Cost % | 2.51 |
N/A
|
N/A
| |||
3-Year Average Share Buyback Ratio | 2.7 |
N/A
|
N/A
| |||
Shareholder Yield % | 2.42 |
N/A
|
N/A
|
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 67.91 |
N/A
|
N/A
| |||
Operating Margin % | 26.81 |
N/A
|
N/A
| |||
Net Margin % | 21.48 |
N/A
|
N/A
| |||
EBITDA Margin % | 34.68 |
N/A
|
N/A
| |||
FCF Margin % | 22.7 |
N/A
|
N/A
| |||
OCF Margin % | 28.19 |
N/A
|
N/A
| |||
ROE % | 25.94 |
N/A
|
N/A
| |||
ROA % | 10.65 |
N/A
|
N/A
| |||
ROIC % | 14.1 |
N/A
|
N/A
| |||
3-Year ROIIC % | 64.04 |
N/A
|
N/A
| |||
ROC (Joel Greenblatt) % | 114.64 |
N/A
|
N/A
| |||
ROCE % | 18.31 |
N/A
|
N/A
| |||
Years of Profitability over Past 10-Year | 10 |
N/A
|
N/A
| |||
Moat Score | 9 |
N/A
|
N/A
| |||
Tariff Resilience Score | 8 |
N/A
|
N/A
|
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 30.04 |
N/A
|
N/A
| |||
Forward PE Ratio | 23.61 |
N/A
|
N/A
| |||
PE Ratio without NRI | 24.77 |
N/A
|
N/A
| |||
Price-to-Owner-Earnings | 29.58 |
N/A
|
N/A
| |||
PEG Ratio | 2.64 |
N/A
|
N/A
| |||
PS Ratio | 6.46 |
N/A
|
N/A
| |||
PB Ratio | 7.35 |
N/A
|
N/A
| |||
Price-to-Free-Cash-Flow | 28.42 |
N/A
|
N/A
| |||
Price-to-Operating-Cash-Flow | 22.89 |
N/A
|
N/A
| |||
EV-to-EBIT | 24.92 |
N/A
|
N/A
| |||
EV-to-Forward-EBIT | 20.73 |
N/A
|
N/A
| |||
EV-to-EBITDA | 19.23 |
N/A
|
N/A
| |||
EV-to-Forward-EBITDA | 17.35 |
N/A
|
N/A
| |||
EV-to-Revenue | 6.67 |
N/A
|
N/A
| |||
EV-to-Forward-Revenue | 6.46 |
N/A
|
N/A
| |||
EV-to-FCF | 29.38 |
N/A
|
N/A
| |||
Price-to-GF-Value | 1.37 |
N/A
|
N/A
| |||
Price-to-Projected-FCF | 2.16 |
N/A
|
N/A
| |||
Price-to-DCF (Earnings Based) | 2.17 |
N/A
|
N/A
| |||
Price-to-DCF (FCF Based) | 2.56 |
N/A
|
N/A
| |||
Price-to-Median-PS-Value | 1.33 |
N/A
|
N/A
| |||
Price-to-Peter-Lynch-Fair-Value | 2.22 |
N/A
|
N/A
| |||
Earnings Yield (Greenblatt) % | 4.01 |
N/A
|
N/A
| |||
FCF Yield % | 3.56 |
N/A
|
N/A
| |||
Forward Rate of Return (Yacktman) % | 13.99 |
N/A
|
N/A
|
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Johnson & Johnson Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 97,929 | ||
| EPS (TTM) ($) | 8.63 | ||
| Beta | N/A | ||
| 3-Year Sharpe Ratio | 0.68 | ||
| 3-Year Sortino Ratio | 1.19 | ||
| Volatility % | 20.87 | ||
| 14-Day RSI | 56.71 | ||
| 14-Day ATR ($) | 8.51 | ||
| 20-Day SMA ($) | 259.26 | ||
| 12-1 Month Momentum % | 53.73 | ||
| 52-Week Range ($) | 148.5 - 275 | ||
| Shares Outstanding (Mil) | 2,409.9 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Johnson & Johnson Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Johnson & Johnson Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Fourth quarter earnings results for 2026 | 2027-01-21 18:45 | In 166 days | ||
| Fourth quarter earnings conference call for 2026 | 2027-01-21 08:30 | In 165 days | ||
| Third quarter earnings conference call for 2026 | 2026-10-13 | In 64 days | ||
| Third quarter earnings results for 2026 | 2026-10-13 | In 64 days | ||
| Guidance call for 2026 | 2026-09-09 11:00 | In 31 days | ||
| USD 1.340000 Cash Dividend | 2026-08-25 | In 15 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-15 08:30 | 255.00 (-1.33%) | ||
| Second quarter earnings results for 2026 | 2026-07-15 06:45 | 255.00 (-1.33%) | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-09 10:00 | 226.00 (-2.40%) | ||
| Bernstein’s 42nd Annual Strategic Decisions Conference | 2026-05-27 11:00 | 231.50 (-1.22%) |
Show
Entries
Johnson & Johnson Frequently Asked Questions
What is Johnson & Johnson(XKAZ:JNJ_KZ)'s stock price today?
The current price of XKAZ:JNJ_KZ is $269.60. The 52 week high of XKAZ:JNJ_KZ is $275.00 and 52 week low is $148.50.
When is next earnings date of Johnson & Johnson(XKAZ:JNJ_KZ)?
The next earnings date of Johnson & Johnson(XKAZ:JNJ_KZ) is 2026-10-13.
Does Johnson & Johnson(XKAZ:JNJ_KZ) pay dividends? If so, how much?
The Dividend Yield %  of Johnson & Johnson(XKAZ:JNJ_KZ) is 1.94% (As of Today), Highest Dividend Payout Ratio of Johnson & Johnson(XKAZ:JNJ_KZ) was 0.5. The lowest was 0.43. And the median was 0.46. The  Forward Dividend Yield % of Johnson & Johnson(XKAZ:JNJ_KZ) is 1.99%. For more information regarding to dividend, please check our Dividend Page.
Press Release
Articles on Johnson & Johnson
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers